Interactive Clinical Calculators & Modeling Tools
Explore our full suite of interactive educational tools in one place. Model your metabolic targets, screen multi-compound stacks for conflicts, estimate biological age, and review GLP-1 titration trial trajectories.
BMI & Metabolic Target
Educational BMI & target model
BMI & Metabolic Target Compound Explorer
Educational modeling tool to explore candidate GLP-1 incretin concepts, synergistic peptides, and recommended in-clinic blood testing panels for provider discussion.
⚖️ Moderate Activity: Balanced metabolic support & baseline organ profiling.
At age 44, natural androgen levels drop ~1–2% annually, accelerating sarcopenic visceral fat accumulation. Starting a physician-directed TRT protocol is strongly indicated alongside metabolic incretin therapy.
Clinical Notice: This tool provides educational guidance based on entered biometrics. It does not constitute a prescription, clinical diagnosis, or automated medication selection. Prescriptions are issued solely after individualized clinical evaluation by a licensed healthcare provider.
AOD-9604
Lipolytic C-Terminal Peptide
Studied for potential adipose lipid mobilization pathways without impacting systemic blood glucose, insulin, or IGF-1 levels.
Tesamorelin
Visceral Adiposity Specialist
Triggers targeted reduction of deep intra-abdominal visceral adipose tissue without suppressing native endocrine pituitary axes.
MOTS-c
Mitochondrial Exercise Mimetic
Activates skeletal muscle glucose clearing via AMPK pathways independent of insulin, accelerating fatty acid oxidation.
NAD+ 1000mg Multi-Dose
Cellular Bioenergetics
Replenishes cellular NAD+ coenzymes for Sirtuin activation and mitochondrial ATP synthesis during caloric regulation.
Signature TRT (Male Over 40)
Targeted androgen optimization: at age 40+, preserves contractile lean muscle mass, reverses sarcopenic decline, and stabilizes energy during GLP-1 caloric deficit.
GLP1 Panel
In-Clinic Diagnostic Panel ($199)Metabolic-focused GLP1 Panel tailored for weight loss: tracks glycemic balance, hepatic enzymes, renal clearance, and atherogenic lipids.
Conflict Checker
Screen multi-compound stacks
Multi-Compound Conflict Checker
Select every GLP-1, peptide, or hormone protocol you're considering. Our registry screens for overlapping receptor agonism and axis overstimulation — flagging combinations that should not be used concurrently. Most compounds stack safely; the tool highlights the few that don't.
Select Compounds to Begin
Check the GLP-1s, peptides, and hormone protocols you're considering. We'll screen for medical conflicts automatically.
This tool screens for known receptor-level and axis-level conflicts for educational planning. It is not a substitute for physician review. Final protocols are physician-directed and pharmacy-fulfilled. If you are uncertain about any combination or how it may interact with your current medications or health conditions, consult your primary care physician for further clarification before proceeding.
Biological Age
PhenoAge cardiometabolic model
Cardiometabolic Biological Age Calculator
Estimate your biological aging rate using clinical biomarkers measured during Alpha 1 Labs in-clinic blood panels (HbA1c, ApoB, hs-CRP, and renal clearance).
Calculated Biological Age
Your cellular regeneration and metabolic clearance are operating younger than your chronological age.
Titration Reference
Weekly escalation concepts & trial weight curves
GLP-1 Titration Reference & Trajectory Model
Educational reference model illustrating standard weekly milligram escalation concepts from published clinical trial literature and projected weight curves. For educational purposes only; all actual dosing is determined by a qualified medical professional.
Tirzepatide
Dual GIPR / GLP-1R Co-Agonist
Projections are modeled from SURMOUNT-1 (Pivotal Phase 3) mean reported values and shown for educational planning only. Individual results vary; titration is physician-guided with tolerance checks at each escalation.
Tirzepatide Weight Trajectory (Y-Axis: Weight in lbs • X-Axis: Time in Weeks)
| Week | Phase | Dose | Projected Weight | Clinical Note |
|---|---|---|---|---|
| Wk 1 | Initiation | 2.5 mg | 218.5 lbs(-0.7%) | 2.5 mg weekly — minimal GI disruption due to GIP nausea buffering. |
| Wk 5 | First Escalation | 5 mg | 212.1 lbs(-3.6%) | 5.0 mg weekly — dual-receptor metabolic activation intensifies. |
| Wk 9 | Second Escalation | 7.5 mg | 204.8 lbs(-6.9%) | 7.5 mg weekly — accelerated visceral adipose mobilization. |
| Wk 13 | Mid-High Escalation | 10 mg | 198 lbs(-10%) | 10 mg weekly — profound lipid profile improvement. |
| Wk 17 | Advanced Escalation | 12.5 mg | 192.3 lbs(-12.6%) | 12.5 mg weekly — approaching maximal efficacy. |
| Wk 21 | Maintenance | 15 mg | 188.3 lbs(-14.4%) | 15 mg weekly — full maintenance per SURMOUNT-1. |
Educational Clinical Reference Only: This tool illustrates standard titration concepts from published clinical literature (Jastreboff et al., NEJM 2022 — up to 20.9–22.5% mean weight reduction at 72 weeks (15 mg maintenance).). It does not constitute medical advice or a personalized dosing recommendation. All dosing, escalations, and therapeutic regimens must be evaluated and prescribed by a qualified medical provider following formal clinical intake.
Ready to Translate Your Numbers Into a Protocol?
Connect with our clinical team to learn more. We assess your baseline, formulate tailored protocols, and deliver compounded medications directly to your door in temperature-monitored cold-chain packaging.